A Prospective Multicenter Open-Label Study of the Effectiveness of Epoetin Beta for Patients with Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Preliminary Result

被引：2

作者：

Chuncharunee, Suporn ^{[1
]}

Kanitsap, Nonglak ^{[2
]}

Suwanban, Tawatchai ^{[3
]}

Khuhapinant, Archrob ^{[4
]}

Uaprasert, Noppacharn ^{[5
]}

Chansung, Kanchana ^{[6
]}

Rattarittamrong, Ekarat ^{[7
]}

Wongkhantee, Somchai ^{[8
]}

Siritanaratanakul, Noppadol ^{[4
]}

Norasetthada, Lalita ^{[7
]}

Nakorn, Thanyaphong Na ^{[5
]}

Charnwiboonsri, Chadchai ^{[9
]}

机构：

[1] Mahidol Univ, Ramathibodi Hosp, Dept Internal Med, Bangkok, Thailand

[2] Thammasat Univ, Dept Internal Med, Pathum Thani, Thailand

[3] Rajavithi Hosp, Dept Internal Med, Bangkok, Thailand

[4] Mahidol Univ, Siriraj Hosp, Dept Med, Bangkok, Thailand

[5] Chulalongkorn Univ, Dept Med, Bangkok, Thailand

[6] Khon Kaen Univ, Dept Internal Med, Khon Kaen, Thailand

[7] Chiang Mai Univ, Dept Internal Med, Chiang Mai, Thailand

[8] Khonkaen Reg Hosp, Dept Internal Med, Khon Kaen, Thailand

[9] Roche Thailand Ltd, Med Dept, Bangkok, Thailand

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.5543.5543

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5543

引用

页数：4

共 50 条

[21] A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium
Jabbour, Elias J.
Short, Nicholas J.
Huang, Xuelin
Maiti, Abhishek
Kadia, Tapan M.
Daver, Naval
Borthakur, Gautam
DiNardo, Courtney D.
Pemmaraju, Naveen
Sasaki, Koji
Estrov, Zeev
Verstovsek, Srdan
Ravandi, Farhad
Alvarado, Yesid
Sekeres, Mikkael A.
Komrokji, Rami S.
Steensma, David P.
DeZern, Amy E.
Roboz, Gail J.
Miller, Darla
Dong, Xiao
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
BLOOD, 2016, 128 (22)
[22] SAFETY AND EFFICACY OF RUXOLITINIB IN PATIENTS WITH DIPSS INTERMEDIATE-1-RISK MYELOFIBROSIS (MF) FROM JUMP: AN OPEN LABEL, MULTICENTER, SINGLE-ARM, EXPANDED-ACCESS STUDY
Passamonti, F.
Zaritskey, A.
Giraldo, P.
Liberati, A. M.
Niederwieser, D.
Palandri, F.
Raanani, P.
Griesshammer, M.
Vannucchi, A. M.
Al-Ali, H. K.
Gupta, V.
Martino, B.
Foltz, L.
Ronco, J. Perez
Ghosh, J.
Bouard, C.
Tavares, R.
HAEMATOLOGICA, 2016, 101 : 93 - 93
[23] Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study
Bose, Prithviraj
McCue, David
Wurster, Sebastian
Wiederhold, Nathan P.
Konopleva, Marina
Kadia, Tapan M.
Borthakur, Gautam
Ravandi, Farhad
Masarova, Lucia
Takahashi, Koichi
Estrov, Zeev
Yilmaz, Musa
Daver, Naval
Pemmaraju, Naveen
Naqvi, Kiran
Rausch, Caitlin R.
Marx, Kayleigh R.
Qiao, Wei
Huang, Xuelin
Bivins, Carol A.
Pierce, Sherry A.
Kantarjian, Hagop M.
Kontoyiannis, Dimitrios P.
CLINICAL INFECTIOUS DISEASES, 2021, 72 (10) : 1755 - 1763
[24] The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study
Yoshiyuki Narahara
Hidenori Kanazawa
Choitsu Sakamoto
Hitoshi Maruyama
Osamu Yokosuka
Satoshi Mochida
Masahito Uemura
Hiroshi Fukui
Yasukiyo Sumino
Yasushi Matsuzaki
Naohiko Masaki
Shigehiro Kokubu
Kiwamu Okita
Journal of Gastroenterology, 2012, 47 : 313 - 320
[25] Outcome Of Patients With IPSS Intermediate (int) Or High Risk Myelodysplastic Syndrome (MDS) According To Donor Availability: A Multicenter Prospective Non Interventional Study For The SFGM-TC and GFM
Robin, Marie
Porcher, Raphael
Ades, Lionel
Raffoux, Emmanuel
Michallet, Mauricette
Francois, Sylvie
Cahn, Jean-Yves
Delmer, Alain
Vigouroux, Stephane
Bay, Jacques-Olivier
Cornillon, Jerome
Huynh, Anne
Nguyen, Stephanie
Vincent, Laure
Maillard, Natacha
Reman, Oumedaly
De Latour, Regis Peffault
Dombret, Herve
Fenaux, Pierre
Socie, Gerard
BLOOD, 2013, 122 (21)
[26] Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure
Jabbour, Elias
Garcia-Manero, Guillermo
Xiao, Lianchun
Najla, Al Ali
Mishra, Asmita
Padron, Eric
Lancet, Jeffrey E.
Bryan, Jeffery
Prescott, Hillary
Steensma, David P.
Sekeres, Mikkael A.
Roboz, Gail J.
List, Alan
Kantarjian, Hagop M.
Komrokji, Rami S.
BLOOD, 2013, 122 (21)
[27] The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study
Narahara, Yoshiyuki
Kanazawa, Hidenori
Sakamoto, Choitsu
Maruyama, Hitoshi
Yokosuka, Osamu
Mochida, Satoshi
Uemura, Masahito
Fukui, Hiroshi
Sumino, Yasukiyo
Matsuzaki, Yasushi
Masaki, Naohiko
Kokubu, Shigehiro
Okita, Kiwamu
JOURNAL OF GASTROENTEROLOGY, 2012, 47 (03) : 313 - 320
[28] The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study
Chue, Pierre
Mandel, Francine S.
Therrien, Francois
CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (06) : 997 - 1005
[29] A phase 2, single-arm, open-label trial to evaluate the effectiveness of darbepoetin alfa for the treatment of anemia in patients with low-risk myelodysplastic syndrome.
Gabrilove, J
Paquette, R
Lyons, R
Mushtaq, C
Sekeres, M
Lam, H
Dreiling, L
BLOOD, 2005, 106 (11) : 714A - 714A
[30] Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"
Sebert, Marie
Chaffaut, Cendrine
Thepot, Sylvain
Orvain, Corentin
Cluzeau, Thomas
Loschi, Michael
Peterlin, Pierre
Chevallier, Patrice
d'Aveni, Maud
Rubio, Marie-Therese
Rauzy, Odile Beyne
Huynh, Anne
Charbonnier, Amandine
Fegueux, Nathalie
Fossard, Gaelle
N'guyen-Quoc, Stephanie
Park, Sophie
Sapena, Rosa
Chermat, Fatiha
Ades, Lionel
Chevret, Sylvie
Fenaux, Pierre
Robin, Marie
BLOOD, 2021, 138 : 1842 - +

← 1 2 3 4 5 →